Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two Years On The Market And Only A 7% Volume Share – J&J Numbers Reveal Infliximab Struggle For US Biosimilars

Executive Summary

Value-wise, Johnson & Johnson’s sales of the Remicade original in the US fell by around a fifth last year with two biosimilars on the market, the originator has just reported. However, thanks in part to what it described as “increased discounts,” J&J was able to retain more than nine-tenths of the infliximab market by volume.

You may also be interested in...

Another Infliximab Biosimilar On Horizon In India?

More competition appears to be in the wings for Remicade in India after the Russian firm Biocad’s biosimilar infliximab was endorsed in India by an expert panel, though there’s little clarity on launch specifics, at least for now.

Erleada Keeps Pace With Xtandi After Positive TITAN Study

Metastatic castration-sensitive prostate cancer could see a marketing race following positive top-line clinical data for Janssen’s apalutamide in the Phase III TITAN study.

US appeals refuses to grant a bar on Zytiga

Generics of Janssen’s Zytiga (abiraterone acetate) blockbuster could enter the US market imminently, after a US Court of Appeals refused twice in quick succession to grant the originator injunctions blocking such launches.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts